Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Purchased by Milestone Asset Management LLC

Milestone Asset Management LLC increased its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 5.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 163,789 shares of the company’s stock after buying an additional 8,662 shares during the quarter. Milestone Asset Management LLC’s holdings in Caribou Biosciences were worth $260,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Erste Asset Management GmbH purchased a new position in shares of Caribou Biosciences during the third quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. grew its position in Caribou Biosciences by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock worth $34,000 after purchasing an additional 6,768 shares during the last quarter. AQR Capital Management LLC acquired a new position in Caribou Biosciences in the second quarter valued at $30,000. Intech Investment Management LLC purchased a new stake in shares of Caribou Biosciences in the third quarter valued at about $43,000. Finally, Point72 DIFC Ltd boosted its stake in shares of Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after buying an additional 23,995 shares during the period. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on CRBU. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Citigroup cut their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Finally, Bank of America lowered their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Caribou Biosciences currently has an average rating of “Buy” and a consensus target price of $10.33.

Caribou Biosciences Trading Down 2.2 %

Shares of CRBU stock opened at $1.31 on Friday. Caribou Biosciences, Inc. has a 12-month low of $1.30 and a 12-month high of $8.33. The company has a market cap of $118.62 million, a price-to-earnings ratio of -0.79 and a beta of 2.34. The stock has a 50 day simple moving average of $1.78 and a 200-day simple moving average of $1.98.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, equities analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.